Is Chick-Fil-A unhealthy? Here's where this Georgia chain ranks among others
But according to a new report from World Atlas, Georgia's homegrown fast-food giant might be less heart-friendly than fans would hope.
A recent analysis by World Atlas assessed menu nutrition profiles and found high levels of calories, saturated fats, sodium, and sugar across offerings from each chain.
See where Chick-Fil-A ranks next to industry staples like Wendy's, McDonald's, and Taco Bell.
Top 10 unhealthy fast-food restaurants in the US
Wendy's
Sonic
Taco Bell
Dairy Queen
KFC
Quiznos
McDonald's
Smashburger
Little Caesars
Chick-fil-A
The report underscores broader public health concerns in Georgia and nationwide. Georgia ranks among the top 20 states with the highest obesity rates in children and adults, according to CDC data.
"An 'original chicken sandwich' with medium waffle fries delivers ~ 750 mg sodium, about one-third of a day's limit, and 800 calories, while sugary lemonade and milkshakes push totals sky-high," World Atlas wrote. "The chain dialed back its 'No Antibiotics Ever' pledge in 2024, though its 2026 cage-free-egg goal remains."
Who founded Chick-fil-A?
Chick-fil-A started in a small diner in Hapeville, Georgia and is now known across the country for making great chicken.
The trio behind Chick-Fil-A is the Cathy family and siblings are Bubba, Dan, and Trudy. The first location opened in 1967 at Atlanta's Greenbriar Mall.
The chain has more than 2,800 restaurants across the U.S. and in Canada and Puerto Rico.
Vanessa Countryman is the Trending Topics Reporter for the the Deep South Connect Team Georgia. Email her at Vcountryman@gannett.com.
This article originally appeared on Savannah Morning News: Is Chick-fil-A really healthier? World Atlas says no.
Solve the daily Crossword
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 hours ago
- Yahoo
CloudWave Maintains SOC 2 Type 2 and HIPAA/HITECH Compliance, Reinforcing Commitment to Delivering Secure, Compliant Cloud and Cybersecurity Solutions for Healthcare
MARLBOROUGH, Mass., August 04, 2025--(BUSINESS WIRE)--CloudWave, a full-service cybersecurity and cloud services provider built exclusively for healthcare, today announced that it has successfully completed its SOC 2 Type 2 and HIPAA/HITECH examination for its Healthcare IaaS and Cybersecurity Services system. The SOC 2 audit was conducted by A-LIGN, the leading provider in cybersecurity compliance trusted by more than 4,000 global organizations to help mitigate cybersecurity risks. "At CloudWave, we are focused on providing healthcare-grade security to protect data and mitigate risk for hospitals for their public cloud, private cloud, and cloud edge," said Erik Littlejohn, president and CEO at CloudWave. "Security is paramount as our customers increasingly leverage our managed cybersecurity and cloud solutions to support daily operations. Our SOC 2 and HIPAA/HITECH compliance recognizes our commitment to using industry-standard controls and best practices to meet or exceed regulatory requirements and protect sensitive patient data and critical systems." Established by the American Institute of Certified Public Accountants (AICPA), the SOC 2 examination is designed for organizations of any size, regardless of industry and scope, to ensure the personal assets of their potential and existing customers are protected. SOC 2 reports are recognized globally and affirm that a company's infrastructure, software, people, data, policies, procedures, and operations have been formally reviewed. "Congratulations to CloudWave for completing their SOC 2 audit, a widely recognized signal of trust and security," said Steve Simmons, COO of A-LIGN. "It's great to work with organizations like CloudWave, who understand the value of expertise in driving an efficient audit and the importance of a high-quality final report." This certification demonstrates CloudWave's continued commitment to compliance and ensures customers have confidence that the required safeguards are in place to protect their data. About CloudWave CloudWave is a full-service cybersecurity and cloud services provider built exclusively for healthcare. The company protects community hospitals and health systems, and specialty healthcare providers with end-to-end solutions that combine secure hosting, IT operations, and 24/7 threat detection and response. With deep experience in cybersecurity, healthcare IT, and infrastructure, CloudWave supports over 350 hospitals and health system environments, hosting more than 140 EHR, clinical, and enterprise applications across private, public, and hybrid cloud environments. CloudWave's services span managed security, risk and compliance, disaster recovery, systems management, and cloud optimization—all delivered with a healthcare-first mindset. Powered by AI-driven security operations and supported by U.S.-based Network and Cybersecurity Tactical Operations Centers staffed 24/7 by certified professionals who understand the clinical and operational realities of healthcare, CloudWave provides a cyber-ready foundation for safe, uninterrupted patient care. To learn more, visit ABOUT A-LIGN A-LIGN is the leading provider of high-quality, efficient cybersecurity compliance programs. Combining experienced auditors and audit management technology, A-LIGN provides the widest breadth and depth of services including SOC 2, ISO 27001, HITRUST, FedRAMP, and PCI. A-LIGN is the number one issuer of SOC 2 and a leading HITRUST and FedRAMP assessor. To learn more, visit View source version on Contacts Jill ColnaSVM Public Relations and Marketing Communicationscloudwave@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
a day ago
- Medscape
Lp(a): Aiming at a Moving Target, Waiting for Ammunition
The evidence implicating high levels of lipoprotein(a), or Lp(a), as a risk predictor for heart attack, stroke, and other cardiovascular conditions has outpaced the science of what to do about the marker. But recent studies may be challenging the prevailing thinking about Lp(a) by showing it may also be predictive of atherosclerotic cardiovascular disease (ASCVD) away from the heart, such as carotid artery stenosis and peripheral artery disease, and that follow-up testing may benefit people with borderline levels of the blood fat. Before clinicians do anything about elevated Lp(a), however, they must first test for it. And experts in interventional cardiology have acknowledged that testing for Lp(a) as part of the cardiometabolic lipid panel lags far behind where it should be. Nishant P. Shah, MD, a specialist in cardiometabolic intervention at Duke University in Durham, North Carolina, led a retrospective study last year of five large US health systems. He and his colleagues found that only 0.4% of patients with ASCVD had been tested for Lp(a). Nishant P. Shah, MD 'Lp(a) testing is extremely low across the country, even in patients who have had established cardiovascular disease or established cardiovascular events,' Shah told Medscape Medical News .'There are disparities in who is getting tested for Lp(a). Our study showed that patients of the Black race, older patients, those with high BMIs, and women are less likely to be tested than others.' In other words, testing lags even further behind in at-risk groups. The lack of testing Shah's group reported among people with ASCVD has been confirmed by other studies. A 2023 study from Germany found similarly low rates, and a US database study the same year reported rates of 0.7% in patients on lipid-lowering therapies for secondary prevention of ASCVD. As a result, the American Heart Association launched a nationwide program, called the Community Health Centers Discovery Project, to bring Lp(a) testing to 20 community health centers across the country. Kaavya Paruchuri, MD 'Research shows that individuals from racially and ethnically diverse backgrounds are both more likely to have elevated Lp(a) levels and to experience disproportionate rates of heart disease,' said Kaavya Paruchuri, MD, a preventive cardiologist at Massachusetts General Hospital in Boston and an American Heart Association volunteer. 'By expanding access to Lp(a) testing in these settings, we can help identify patients at increased risk and support more informed conversations about prevention and risk-reduction strategies.' Barriers to Testing The barriers to more widespread testing are 'multifactorial,' Shah said. The relevance of Lp(a) has only emerged in the past decade or so, leaving generations of cardiologists and primary care providers lacking education about the marker. No Lp(a)-lowering drug has been approved, and while no fewer than six investigational agents are in clinical trials, none is on the brink of approval. The 2018 clinical guidelines from the American Heart Association/American College of Cardiology recommended selective screening; that is, people who have severe high cholesterol, ASCVD, or a family member who's had early ASCVD. In Europe, clinical guidelines recommend Lp(a) screening for all adults to identify those with high levels of the substance. 'Unfortunately, awareness of Lp(a) as a cardiovascular risk factor remains low amongst both patients and clinicians,' Paruchuri said. 'Furthermore, clinicians may be hesitant to order Lp(a) as there is no clearly defined treatment available to lower Lp(a), and they are unsure how to optimally handle abnormally elevated Lp(a) results.' Shah also noted that some health insurance plans do not cover the test. 'Providers may not know if the test is covered by insurance or not,' he said. The 2018 US guidelines noted that Lp(a) is a modified form of low-density lipoprotein (LDL) that appears to possess atherogenic potential. The consensus among researchers who have investigated Lp(a) is that it is a genetic biomarker. As such, levels may not vary from one test to the next unless Lp(a) is targeted with a drug. Lp(a) levels ≥ 50 mg/dL are considered to be elevated. Despite the lack of a treatment, experts said one case for the cost-effectiveness of Lp(a) testing is that it would be a once-and-done assay in most patients with risk factors for ASCVD. Emerging Revelations About Lp(a) 'I don't have the Lp(a) test repeated for patients, as I have not seen any strong evidence supporting that it being reduced or increased changes cardiovascular disease or other health issues,' Robert C. Block, MD, MPH, preventive cardiologist at the University of Rochester Medical Center, in Rochester, New York, told Medscape Medical News . 'Not repeating it also is more cost-effective. My point when seeing patients is that this makes sense until we have clinical trial data supporting that lowering it via an agent changes risk.' Robert C. Block, MD, MPH But a just-published study of almost 12,000 adult patients at three Mayo Clinic locations may upend that thinking. The Mayo researchers said that after one Lp(a) test, normal or high levels typically do not change: 96.4% of people with normal Lp(a) and 89.9% with high levels in the study had the same levels of the molecule when they were retested. However, the study did find that almost half of the people with borderline Lp(a) — a range of 30 to 50 mg/dL — changed their category (normal, borderline, or high) after retesting, and a quarter of them had a change greater than 10 mg/dL. Women, patients who had ASCVD, those with LDL cholesterol (LDL-C) levels of ≥ 100 mg/dL, or those on statin therapy had higher odds of a change in Lp(a) of > 10 mg/dL. 'These findings highlight that patients with borderline Lp(a) levels may require more than one Lp(a) measurement for a comprehensive ASCVD risk assessment,' the authors of the study wrote. Also adding a dimension to the understanding of Lp(a) is a large database analysis in the UK that has linked high Lp(a) to peripheral artery disease and carotid artery stenosis, among other extracoronary ASCVDs. Patients in the study — which used > 70 mg/dL (or 150 nmol/L) as a threshold for predicting ASCVD complications — with peripheral artery disease and elevated Lp(a) were at 57% greater risk for having a major adverse limb event than patients with normal concentrations of the molecule. Those with carotid stenosis and high Lp(a) had a 40% greater risk for stroke than patients with normal levels. According to the researchers, lowering Lp(a) concentrations by 35 mg/dL (75 nmol/L) would reduce the risk for incident peripheral artery disease by 18% and for incident carotid stenosis by 17%. 'Participants with established extracoronary atherosclerotic vascular disease and elevated Lp(a) concentrations are at high risk for progression to major atherosclerotic complications,' they reported. Again, however, how to reduce Lp(a) is unclear. Consistent intake of niacin is one strategy for reducing Lp(a), the UK researchers stated, but only 77 (0.02%) of the 460,544 participants in the analysis were taking the nutrient. Niacin has had its own star-crossed history as a risk-reduction strategy in ASCVD. Both the 2011 AIM-HIGH trial and the 2014 HPS2-THRIVE study found that people who took niacin supplements did not reduce their risk for ASCVD, although participants in AIM-HIGH on niacin had a 25% reduction in Lp(a) levels. These studies moved the consensus away from niacin therapy. Another recent revelation about Lp(a) is its apparent independence from LDL-C. Lowering LDL-C with statins does not affect cardiac risks associated with elevated Lp(a), said Sotirios Tsimikas, MD, who was the corresponding author for a 2024 meta-analysis on the question. Sotirios Tsimikas, MD 'Lp(a) is an independent risk factor at all levels of achieved LDL when you treat somebody with an LDL-lowering agent,' said Tsimikas, a cardiologist at the Sulpizio Cardiovascular Center and director of vascular medicine at the University of California San Diego (UCSD) Health. 'The implication is you have to treat it as your own independent risk factor and not assume that when you treat the LDL-C, even at very low levels, that you reduce Lp(a)-mediated risk.' In a study, patients with Lp(a) > 50 mg/dL but in the lowest quartile of LDL-C after treatment — in the 3.1-77 mg/dL range — had a 38% greater ASCVD risk than those with Lp(a) levels below the 50 mg/dL threshold. Tsimikas said this study built on research his group published in 2018. 'What this paper showed with more granularity was that the LDL level that was achieved in the statin trials did not reduce the Lp(a) risk,' he said. The State of Clinical Trials Block and his group have reported on clinical trials of six investigative therapies targeting Lp(a). Three subcutaneous therapies are in phase 3 trials: Pelacarsen, an antisense oligonucleotide that has demonstrated an 80% reduction in Lp(a); and two small interfering RNAs (siRNAs), olpasiran and lepodisiran, both of which have demonstrated up to a 98% reduction in Lp(a). Likewise, three agents are in phase 2 trials: Zeriasiran, a subcutaneous siRNA agent that has shown up to a 98% reduction in Lp(a); and two oral agents, muvalaplin, an Lp(a) inhibitor that has demonstrated up to an 85% reduction in levels of the molecule, and obicetrapib, a cholesterol ester transport protein inhibitor that has shown up to a 57% reduction in the substance and is used in conjunction with evolocumab. Deeper in the pipeline is at least one potential one-time gene therapy, CTX320, which is in preclinical stages. The pelacarsen trial is scheduled for completion early next year. The olpasiran trial is scheduled for completion at the end of 2026. 'We're right on the cusp of knowing if we lower Lp(a), do we get a benefit that's clinically meaningful?' Tsimikas said. Modify What You Can — Wait for the Calvary Despite the lack of commercially available therapies, providers can employ several interventions to manage ASCVD risks in patients with elevated levels of Lp(a). 'The theme here is to modify what you can modify until we have more directed therapy with good clinical trial outcomes,' Shah said. 'Drop LDL as low as you can. Consider starting aspirin therapy, especially if patients have multiple risk factors — and absolutely they should be on aspirin therapy if they've had a prior cardiovascular event. Then I look to modify other things. Are they hypertensive? Can I get them better? Are they obese? Can I reduce their weight? Do they have diabetes? What can we do to control this more?' First-degree relatives of people with high Lp(a) levels should get their Lp(a) levels tested, he added. Motivated patients could be encouraged to enroll in a clinical trial. 'As more people understand that there are changes you can make today, they may be more likely to test for Lp(a),' Shah said. Until clinical trial results are reported, clinicians are in a 'gray zone,' Tsimikas said. To get through that 'gray zone,' more education of providers and patients is needed, healthcare systems need to support more widespread Lp(a) testing, and insurance companies need to cover testing, he said. 'What I'm seeing is that a lot of physicians have become aware of Lp(a), and I'm seeing a lot of testing that normally I wouldn't,' Tsimikas said. 'I think the tide is already turning on this.' Block has no relevant relationships to disclose. Paruchuri reported having financial relationships with Allelica, Amgen, Apple, AstraZeneca, Boston Scientific, Genentech/Roche, Ionis, Novartis, and NewAmsterdam Pharma. Shah reported having received research grants from Amgen and Janssen and is a consultant/advisor for Esperion, Amgen, and Novartis. Tsimikas is a co-inventor and receives royalties from patents owned by UCSD. He is also a cofounder and holds equity in Oxitope and Kleanthi Diagnostics and has a dual appointment at UCSD and Ionis Pharmaceuticals.
NBC News
27-07-2025
- NBC News
A Texas candy company switched to natural dyes — but it wasn't easy
Natural dyes, which are derived from plants, produce, spices and minerals, have not been scrutinized as closely by researchers for their health impact or the potential for contamination, experts say. They are also not subject to the same stringent testing requirements as synthetic dyes. That has raised concerns among some food experts and consumer advocates about the unintended consequences of this shift — and whether it will actually make food safer and healthier. 'The important thing to remember with all colors, whether natural or synthetic, is that they are nothing more than marketing tools for food companies, to make foods look a certain way,' said Thomas Galligan, a toxicologist who works for the Center for Science in the Public Interest, an advocacy group. 'At the end of the day, they aren't strictly necessary. And so it's important to weigh the risk against the benefit.' Eric Atkinson says he never thought synthetic dyes were unsafe. But when he read the ingredient lists for his company's candies, which his family has been making since the Great Depression, they always struck him as out of place. About 12 years ago, the company finally decided to make the leap. 'We were so close to being all natural or all simple ingredients that we just went ahead and went there,' he said. He knew how critical it was to get the color right for the Chick-O-Stick, the company's most recognizable product. All the packaging for the candy mimics the color of the product, which Atkinson describes as 'amber.' 'They say in the industry that taste is king, but color is queen,' he said. 'The queen is very important.' Working with food scientists for dye manufacturers, the company's quality control team started testing mixtures of natural dyes to replicate the Chick-O-Stick's signature hue. After years of testing, they came up with a combination of dyes derived from turmeric and vegetable juice — first trying beets before settling on radishes. But they later discovered that the color faded under LED light. This year, they switched again to annatto, a popular natural colorant made from the seeds of the achiote tree. Another surprise was the funky smell that came from some of the natural colors. Atkinson recalls one particularly pungent dye made from red cabbages that smelled like rotting garbage, though the odor quickly dissipated when the candy reached the cooking step, where it's heated to over 300 degrees. That wasn't the end of the challenges. Unlike synthetic dyes, which are easily produced in U.S. labs, the ingredients that form natural dyes are frequently imported. That introduces a host of complexities, including logistics, costs and product safety issues. In March 2021, a container ship got stuck in the Suez Canal, making headlines worldwide. It also created a new headache for Atkinson: The ship was carrying the radishes used to create the Chick-O-Stick color at the time, sending the company scrambling for alternatives. Even without such obstacles, it can be tough to find enough raw materials for natural dyes. It takes a considerable amount of seasonally grown produce — whether it's radishes, red cabbages, blueberries or golden beets — to make dyes from fruits and vegetables. Carmine, a vibrant red colorant, is made from cactus-dwelling insects in Central and South America; 70,000 of those insects are required to create just over 2 pounds of dye. Sourcing challenges often mean higher prices: One major dye manufacturer recently estimated that natural dyes cost about 10 times as much as the synthetic versions. And then it can be a matter of convincing consumers. Though the color and appearance of the Chick-O-Stick had remained the same, not everyone was happy about the new formulation of a classic candy. 'We had a lot of pushback when we went to the natural colors,' said Atkinson. 'Most of the feedback that we got was, 'Quit changing our Chick-O-Stick.'' Still, sales stayed steady, Atkinson said.
